Indian-based Dr Reddy’s Laboratories has collaborated with TR-Pharm to commercialise three biosimilar drugs in Turkey.
Biosimilar is a biopharmaceutical drug that is designed to have active properties similar to one that has previously been licensed.
As per the terms of the strategic collaboration agreement signed between the companies, the biosimilars will be registered and subsequently commercialised.
Upon completion of its facility investment, TR-Pharm will manufacture the drug substance and drug product.
The partnership will be a key component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. TR-Pharm has started laying out the groundwork for the technology transfer.
TR-Pharm general manager Mehmet Göker said: "Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"This agreement will not only enable more affordable medication, but also support our research and development initiatives by building expertise within the country.
"We are pleased to have already started laying out the groundwork for manufacturing with Dr. Reddy’s for high-quality biosimilar products."
Dr. Reddy’s will also be able to expand global footprint of its biosimilar business.
Dr. Reddy’s India and Emerging countries branded markets head M V Ramana said: "Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high-quality biosimilar products.
"Dr. Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make it happen in Turkey."
Dr Reddy’s produces products for applications, including gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives.
Image: Dr Reddy’s biopharma finished dosage unit III in India. Photo: courtesy of Arichuvadi.
